Effectiveness and safety of blonanserin monotherapy for first-episode schizophrenia with and without prominent negative symptoms: A prospective study

Table 2 Adverse reactions (n = 653), n (%)

	Mild		Moderate		Severe
	Patients	Cases, n	Patients	Cases, n	Patients	Cases, n
Total ADRs	47 (7.2)	71	24 (3.7)	32	5 (0.8)	5
Neurological disorders
Akathisia	24 (3.7)	25	12 (1.8)	12	1 (0.2)	1
Tremor	9 (1.4)	9	6 (0.9)	6	0 (0)	0
Dystonia	7 (1.1)	7	6 (0.9)	6	1 (0.2)	1
Parkinsonism	5 (0.8)	5	5 (0.8)	5	0 (0)	0
Investigations
Weight gain	4 (0.6)	4	0 (0)	0	0 (0)	0
Increased heart rate	3 (0.5)	3	0 (0)	0	0 (0)	0
Abnormal liver function	2 (0.3)	2	0 (0)	0	0 (0)	0
Sleep disorders	5 (0.8)	5	0 (0)	0	0 (0)	0
Gastrointestinal disorders	3 (0.5)	3	1 (0.2)	1	0 (0)	0
Kidney and urinary disorders	1 (0.2)	2	1 (0.2)	1	1 (0.2)	1

Adverse reactions with the total frequency ≥ 0.3% were listed. Sleep disorders included insomnia and drowsiness, gastrointestinal disorders included constipation and nausea, and kidney and urinary disorders included dysuria and urinary tract infection. ADRs: Adverse reactions.